AVANIR Pharmaceuticals Financial Statements
AVANIR Pharmaceuticals Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | September |
© 2009 Morningstar, Inc. Financial Data provided by
AVANIR Pharmaceuticals Income Statement
| 2008 | 2007 | 2006 | |
|---|---|---|---|
| Revenue ($ mil.) | 7.0 | 9.2 | 15.2 |
| Gross Profit ($ mil.) | 6.7 | 4.6 | 7.3 |
| Operating Income ($ mil.) | (15.4) | (27.1) | (58.2) |
| Total Net Income ($ mil.) | (20.5) | (20.9) | (58.9) |
| Diluted EPS (Net Income) | (0.30) | (0.53) | (2.04) |
AVANIR Pharmaceuticals Quarterly Statements
| Quarter Ending Jun 09 | Quarter Ending Mar 09 | Quarter Ending Dec 08 | |
|---|---|---|---|
| Revenue ($ mil.) | 0.6 | 0.8 | 1.8 |
| Gross Profit ($ mil.) | -- | 0.8 | 1.7 |
| Operating Income ($ mil.) | (5.0) | (4.9) | (5.2) |
| Total Net Income ($ mil.) | (5.0) | (5.0) | (5.3) |
| Diluted EPS (Net Income) | (0.06) | (0.06) | (0.07) |
AVANIR Pharmaceuticals Stock Quote & Chart
11/09/09 16:00:02 EST •
NASDAQ •
1.86
•
 +0.0300
•
+1.6393 %
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
AVANIR Pharmaceuticals Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 33.56 | 16.39 | 7.00 |
| Price/Earnings Ratio | (7.00) | 370.37 | 25.45 |
| Price/Book Ratio | 9.62 | 3.51 | 6.74 |
| Price/Cash Flow Ratio | (7.32) | 79.37 | 43.48 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed AVANIR Pharmaceuticals Financial Ratios
AVANIR Pharmaceuticals Competitive Intelligence
| Bristol-Myers Squibb | Eli Lilly | GlaxoSmithKline | |
|---|---|---|---|
| Annual Sales ($ mil.) | 20,597.0 | 20,378.0 | 35,244.6 |
| Employees | 35,000 | 40,500 | 99,003 |
| Market Cap ($ mil.) | 44,572.1 | 39,560.8 | 114,528.4 |
Competitive Landscape
